Cantargia AB Cash Flow Conversion Efficiency

Latest as of September 2025: 0.943x

Cantargia AB cash flow conversion efficiency. Based on the latest financial reports, Cantargia AB (CANTA) has a cash flow conversion efficiency ratio of 0.943x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr280.72 Million ≈ $30.21 Million USD) by net assets (Skr297.57 Million ≈ $32.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cantargia AB (2011–2024)

Cash flow conversion efficiency of Cantargia AB from 2011 to 2024. This chart illustrates how Cantargia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Cantargia AB for real-time trading data and today's change.

Cantargia AB Cash Flow Conversion Ratio Explained

Cantargia AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cantargia AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cantargia AB ranked by their cash flow conversion efficiency. Also see CANTA market cap overview for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
IBKS No. 15 Special Purpose Acquisition Co. Ltd.
KQ:373200
-0.069x
TOVIS Co.Ltd
KQ:051360
0.035x
Li Cheng Enterprise Co Ltd
TW:4426
-0.022x
Plastiques du Val de Loire
PA:PVL
0.215x
TPXIMPACT HOLDINGS LS-01
F:9L7
N/A
Aman Agrindo
JK:GULA
0.010x
Senko Co. Ltd
KQ:347000
0.022x
Kwang Ming Silk Mill Co Ltd
TWO:4420
-0.105x

Annual Cash Flow Conversion Efficiency for Cantargia AB (2011–2024)

The table below shows the annual cash flow conversion efficiency of Cantargia AB from 2011 to 2024. Review cash generation quality of Cantargia AB to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr116.30 Million
≈ $12.52 Million
Skr-162.75 Million
≈ $-17.51 Million
-1.399x +17.63%
2023-12-31 Skr168.74 Million
≈ $18.16 Million
Skr-286.66 Million
≈ $-30.85 Million
-1.699x -84.45%
2022-12-31 Skr389.68 Million
≈ $41.94 Million
Skr-358.92 Million
≈ $-38.62 Million
-0.921x -41.63%
2021-12-31 Skr532.75 Million
≈ $57.33 Million
Skr-346.44 Million
≈ $-37.28 Million
-0.650x -270.89%
2020-12-31 Skr891.93 Million
≈ $95.99 Million
Skr-156.39 Million
≈ $-16.83 Million
-0.175x +77.58%
2019-12-31 Skr142.27 Million
≈ $15.31 Million
Skr-111.25 Million
≈ $-11.97 Million
-0.782x -15.81%
2018-12-31 Skr155.04 Million
≈ $16.69 Million
Skr-104.69 Million
≈ $-11.27 Million
-0.675x -304.30%
2017-12-31 Skr246.12 Million
≈ $26.49 Million
Skr-41.10 Million
≈ $-4.42 Million
-0.167x +84.31%
2016-12-31 Skr37.13 Million
≈ $4.00 Million
Skr-39.53 Million
≈ $-4.25 Million
-1.065x +1.35%
2015-12-31 Skr28.05 Million
≈ $3.02 Million
Skr-30.28 Million
≈ $-3.26 Million
-1.079x -164.11%
2014-12-31 Skr4.10 Million
≈ $440.95K
Skr6.90 Million
≈ $742.32K
1.683x +163.81%
2013-12-31 Skr3.13 Million
≈ $337.02K
Skr-8.26 Million
≈ $-889.18K
-2.638x -114.81%
2012-12-31 Skr3.08 Million
≈ $331.15K
Skr-3.78 Million
≈ $-406.73K
-1.228x +35.02%
2011-12-31 Skr1.54 Million
≈ $165.99K
Skr-2.92 Million
≈ $-313.74K
-1.890x --

About Cantargia AB

ST:CANTA Sweden Biotechnology
Market Cap
$44.55 Million
Skr413.94 Million SEK
Market Cap Rank
#22145 Global
#415 in Sweden
Share Price
Skr1.67
Change (1 day)
-3.20%
52-Week Range
Skr1.28 - Skr6.20
All Time High
Skr58.00
About

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more